Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Molecular Cancer|April 20, 2024
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulationAnder Puyalto, María Rodríguez-Remírez, Inés López, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2025
Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint InhibitorsMadeleine Di Frisco, Miguel F Sanmamed, José María Ferrández, et al.Journal of Translational Medicine|March 5, 2023
Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patientsBenito Farina, Ana Delia Ramos Guerra, David Bermejo-Peláez, et al.The Lancet. Neurology|January 21, 2023
Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trialWolfgang Köhler, Marc Engelen, Florian Eichler, et al.Scientific Reports|January 28, 2017
Galectin-3 released in response to traumatic brain injury acts as an alarmin orchestrating brain immune response and promoting neurodegenerationPing Kei Yip, Alejandro Carrillo-Jimenez, Paul King, et al.Cancer Research|July 25, 2025
Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to ImmunotherapyEsther Redin, Nerea Otegui, Mirentxu Santos, et al.The Journal of Biological Chemistry|April 6, 2021
Wild-type sTREM2 blocks Aβ aggregation and neurotoxicity, but the Alzheimer's R47H mutant increases Aβ aggregationAnna Vilalta, Ye Zhou, Jean Sevalle, et al.Cancers|October 31, 2020
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T CellsIosune Baraibar, Marta Roman, María Rodríguez-Remírez, et al.Acta Neuropathologica|April 22, 2019
Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer's diseaseAntonio Boza-Serrano, Rocío Ruiz, Raquel Sanchez-Varo, et al.Cell Reports|October 17, 2019
TET2 Regulates the Neuroinflammatory Response in MicrogliaAlejandro Carrillo-Jimenez, Özgen Deniz, Maria Victoria Niklison-Chirou, et al.Pageof 5